| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $20,885 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Hunter Heidi | director | 1 | $20,885 | 0 | $0 | $20,885 |
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Over the last 12 months, insiders at IO Biotech, Inc. have bought $20,885 and sold $0 worth of IO Biotech, Inc. stock.
On average, over the past 5 years, insiders at IO Biotech, Inc. have bought $18.51M and sold $945,016 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hunter Heidi (director) — $20,885.
The last purchase of 15,000 shares for transaction amount of $20,885 was made by Hunter Heidi (director) on 2025‑05‑30.
| 2025-05-30 | Hunter Heidi | director | 15,000 0.0223% | $1.39 | $20,885 | -40.13% | ||
| 2024-12-23 | Sullivan Amy | Chief Financial Officer | 10,250 0.0148% | $0.83 | $8,483 | +10.16% | ||
| 2024-12-23 | Zocca Mai-Britt | Chief Executive Officer | 12,500 0.0177% | $0.81 | $10,120 | +10.16% | ||
| 2024-12-23 | Ahmad Qasim Iftikhar | Chief Medical Officer | 31,350 0.0463% | $0.85 | $26,553 | +10.16% | ||
| 2024-12-23 | Smith Devin Whittemore | General Counsel | 12,000 0.017% | $0.81 | $9,720 | +10.16% | ||
| 2024-07-26 | Sale | Novo Holdings A/S | 10 percent owner | 23,478 0.0362% | $1.31 | $30,787 | -20.93% | |
| 2024-07-25 | Sale | Novo Holdings A/S | 10 percent owner | 51,522 0.0774% | $1.33 | $68,339 | -23.88% | |
| 2024-05-10 | Sale | Novo Holdings A/S | 10 percent owner | 658,809 0.8518% | $1.22 | $802,495 | -26.57% | |
| 2024-02-09 | Sale | Novo Holdings A/S | 10 percent owner | 658,809 0.8023% | $1.50 | $988,411 | -23.93% | |
| 2023-11-22 | Burkavage Brian | Chief Accounting Officer | 5,000 0.0076% | $1.03 | $5,175 | +31.43% | ||
| 2023-11-21 | Burkavage Brian | Chief Accounting Officer | 5,000 0.0074% | $0.99 | $4,950 | +36.63% | ||
| 2023-08-09 | Novo Holdings A/S | 10 percent owner | 2.47M 9.534% | $2.02 | $5M | -19.17% | ||
| 2023-08-09 | Vivo Capital IX, LLC | 10 percent owner | 3.16M 11.4408% | $1.90 | $6M | -19.17% | ||
| 2023-03-17 | Sullivan Amy | Chief Financial Officer | 25,000 0.1017% | $2.32 | $58,018 | -8.08% | ||
| 2021-11-09 | Lundbeckfond Invest A/S | 10 percent owner | 2.14M 51.9475% | $14.00 | $30M | -62.27% | ||
| 2021-11-09 | Novo Holdings A/S | 10 percent owner | 325,000 7.8787% | $14.00 | $4.55M | -62.27% | ||
| 2021-11-09 | Vivo Capital IX, LLC | 10 percent owner | 650,000 15.7574% | $14.00 | $9.1M | -62.27% | ||
| 2021-11-09 | Nielsen Jack | director | 650,000 15.7574% | $14.00 | $9.1M | -62.27% | ||
| 2021-11-09 | HBM Healthcare Investments (Cayman) Ltd. | 10 percent owner | 325,000 7.8787% | $14.00 | $4.55M | -62.27% | ||
| 2021-11-09 | Andersson Claus A. | director | 75,000 1.8182% | $14.00 | $1.05M | -62.27% |
| Hunter Heidi | director | 15000 0.0208% | $4,200.00 | 1 | 0 | |
| Lundbeckfond Invest A/S | 10 percent owner | 6049452 8.408% | $1.69M | 1 | 0 | <0.0001% |
| Novo Holdings A/S | 10 percent owner | 4354449 6.0521% | $1.22M | 2 | 4 | <0.0001% |
| Vivo Capital IX, LLC | 10 percent owner | 3157894 4.3891% | $884,210.32 | 2 | 0 | <0.0001% |
| Nielsen Jack | director | 3015545 4.1912% | $844,352.60 | 1 | 0 | <0.0001% |
| HBM Healthcare Investments (Cayman) Ltd. | 10 percent owner | 2690545 3.7395% | $753,352.60 | 1 | 0 | <0.0001% |
| Andersson Claus A. | director | 1791490 2.4899% | $501,617.20 | 1 | 0 | <0.0001% |
| Malier Vanessa | director | 958559 1.3323% | $268,396.52 | 1 | 0 | <0.0001% |
| Sullivan Amy | Chief Financial Officer | 84632 0.1176% | $23,696.96 | 2 | 0 | +1.04% |
| Zocca Mai-Britt | Chief Executive Officer | 49891 0.0693% | $13,969.48 | 1 | 0 | +10.16% |
| Ahmad Qasim Iftikhar | Chief Medical Officer | 31350 0.0436% | $8,778.00 | 1 | 0 | +10.16% |
| Smith Devin Whittemore | General Counsel | 16938 0.0235% | $4,742.64 | 1 | 0 | +10.16% |
| Burkavage Brian | Chief Accounting Officer | 11500 0.016% | $3,220.00 | 2 | 0 | +34.03% |
$14,315,062 | 61 | -6.21% | $27.51M | |
$448,545 | 49 | -21.85% | $17.86M | |
$6,204,522 | 45 | 1.91% | $17.51M | |
$6,818,859 | 36 | 47.81% | $23.73M | |
$94,610,184 | 33 | -23.48% | $28.2M | |
$711,440 | 26 | 20.43% | $26.59M | |
$114,619,342 | 20 | -7.41% | $15.87M | |
IO Biotech, Inc. (IOBT) | $74,023,014 | 16 | -23.35% | $20.15M |
$25,487,383 | 15 | -4.37% | $14.15M | |
$33,809,329 | 11 | -64.88% | $28.36M | |
$13,486,672 | 11 | 82.26% | $18.41M | |
$70,584,874 | 10 | 3.97% | $22.71M | |
$13,595,542 | 9 | -16.74% | $26.07M | |
$8,731,108 | 7 | 153.66% | $21.29M | |
$206,317 | 7 | -29.23% | $14.1M | |
$147,504 | 5 | -36.70% | $18.71M | |
$10,105,079 | 5 | -26.86% | $18.35M | |
$18,186,879 | 4 | 49.41% | $20.16M | |
$500,000 | 1 | -22.94% | $14.57M |
| Increased Positions | 8 | +25% | 1M | +11.97% |
| Decreased Positions | 13 | -40.63% | 3M | -32.76% |
| New Positions | 5 | New | 1M | New |
| Sold Out Positions | 5 | Sold Out | 438,734 | Sold Out |
| Total Postitions | 27 | -15.63% | 8M | -20.8% |
| Novo Holdings A/S | $1,686.00 | 3.49% | 2.51M | -841,996 | -25.1% | 2025-09-30 |
| Ikarian Capital, Llc | $1,024.00 | 2.12% | 1.53M | +2M | New | 2025-09-30 |
| Millennium Management Llc | $934.00 | 1.93% | 1.39M | +1M | New | 2025-09-30 |
| Marshall Wace, Llp | $706.00 | 1.46% | 1.05M | -1M | -50% | 2025-09-30 |
| Bank Of America Corp /De/ | $537.00 | 1.11% | 799,953 | -815,121 | -50.47% | 2025-09-30 |
| Morgan Stanley | $448.00 | 0.93% | 668,402 | +14,724 | +2.25% | 2025-09-30 |
| Boothbay Fund Management, Llc | $397.00 | 0.82% | 591,180 | +591,180 | New | 2025-09-30 |
| Renaissance Technologies Llc | $367.00 | 0.76% | 547,315 | +408,015 | +292.9% | 2025-09-30 |
| Point72 Asset Management, L.P. | $168.00 | 0.35% | 250,000 | +250,000 | New | 2025-09-30 |
| Xtx Topco Ltd | $120.00 | 0.25% | 179,207 | +150,018 | +513.95% | 2025-09-30 |